Pharmaceutical patent strategy is often discussed like a binary choice: cut losses or keep fighting.
But the real question isn’t whether a patent is “good” or “bad.” It’s whether your portfolio is built to win—or whether it’s quietly turning into an ex…

The clock is already ticking—so why are so many commercial market access teams waiting until it’s too late?
In pharma, timing isn’t just a competitive advantage. It’s the difference between capturing value and watching it evaporate.
Drug patent cliffs …

Pharma procurement teams are sitting on a quiet risk radar—and most of them never turn it on.
Paragraph IV filings are often treated like a legal event: something for counsel to track, something for business development to react to, something for finan…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…

Sell the line—before the patent breaks.
In pharma manufacturing, timing isn’t a “nice-to-have.” It’s the difference between being a preferred supplier and being an afterthought.
As patents approach expiration, generic and biosimilar players don’t jus…